Isomorphic Labs raised $2.1 billion in a Series B to advance AI drug discovery.
- Amount
- $2.1B
- Stage
- Series B
- Announced
- 12 May 2026
- Lead
- Thrive Capital
- Other investors
- Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund
- Use of funds
- Continued development and deployment of its AI drug design engine, pipeline expansion, and global hiring.
- Checked
- Amount and date matched across 3 press sources